Other News To Note
• Chrysalis Biotherapeutics Inc., of Galveston, Texas, received a $1 .5 million contract from the National Cancer Institute to continue its development of Chrysalin, a naturally occurring regenerative peptide, to mitigate radiotherapy-induced damage to normal brain tissue.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.